Citation:Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI, et al 2014

From Clinical Guidelines Wiki

Citation


Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. Gastrointest Endosc 2014 Feb 1;79(2):242-56 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/24079411.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Is surveillance cost-effective for follow-up of patients with BO?Dr Louisa Gordoncompleted
What are the risk factors for progression from non-dysplastic BO to high-grade dysplasia or adenocarcinoma?Professor David Whiteman B Med Sci, MBBS (Hons) PhD FAFPHMcompleted
Are there groups of patients with non-dysplastic BO that require more frequent surveillance?Dr Henry Tocompleted
Are there groups of patients with BO that can be discharged from surveillance?Conjoint Associate Professor Philip Craigcompleted

Compare quality appraisals for each clinical question

Cited by

  1. Is surveillance cost-effective for follow-up of patients with BO?